Analyst sentiment on AbbVie stock

What happened: AbbVie (ABBV) reported strong Q1 results, beating revenue estimates by $284M and raising full-year EPS guidance to $14.28. Key drugs Skyrizi and Rinvoq grew by 31% and 23% respectively, with a 65% free cash flow payout ratio securing the post-Humira dividend. Over the past decade, ABBV has delivered a 400% return, outperforming the S&P 500 by 139 percentage points. Analysts project ABBV to hit $300, a 35% increase from current levels, based on its forward earnings multiple and revenue growth.

Market impact: The bullish sentiment around ABBV is driving investor confidence in the pharmaceutical sector, particularly in companies with strong pipeline growth and robust dividend payouts. This narrative is pushing funds into defensive pharma stocks, seeking stability and income in an uncertain market.

What to watch next: AbbVie's next quarterly earnings report on July 27, 2026, will provide further insight into the company's growth trajectory. Additionally, investors should monitor the European Hematology Association 2026 Congress in Stockholm, Sweden, on June 12, 2026, for updates on AbbVie's pipeline, including its fixed-duration venetoclax-based combination therapy.